Continuing to invest in its gene therapy capabilities, Vertex Pharmaceuticals has agreed to partner with Affinia Therapeutics in a deal worth up to US$1.6 B. With the deal, Vertex gains access to Affinia’s library of adeno-associated virus capsids that will complement Vertex’s gene therapies for the treatment of Duchenne muscular dystrophy, myotonic dystrophy 1 and cystic fibrosis.